With the ongoing shift in Australia to more biosimilar, generic and second brand medicines, from 1 January 2020, Sanofi Australia will launch a second brand of insulin glargine 100 units/mL, OPTISULIN®. 

OPTISULIN® is the same formulation as LANTUS® and is available in the same familiar presentations and devices, including the SoloStar® pre-filled device and cartridges for use in either AllStar Pro® and JuniorStar® reusable pens. It requires no dose adjustment when transitioning from LANTUS® and patients transitioning to OPTISULIN® should continue to administer their dose at the same of the day and monitor their blood glucose levels as directed by their treating clinician1.

With the introduction of Optisulin®, insulin glargine 100 units/mL, Sanofi will now also begin a six-month program to transition its other insulin glargine 100 units/mL brand, Lantus®, from the PBS.  

Lantus will be removed from the PBS from 1 July 2020, allowing enough time for Australian patients to discuss a transition to another insulin glargine 100 units/mL when they next visit their treating clinician or pharmacist. 

Sanofi is committed to supporting patients and healthcare professionals during this transition. If you would like more information, please contact the following phone numbers below. 

Patient Support

Through a partnership with the Australian Diabetes Educators Association (ADEA), Sanofi insulin patients can call 1800 2 SIMPLE (1800 2 746 753) and speak with a Credentialled Diabetes Educator (CDE), to receive independent advice related to their diabetes management. This includes a translator service and is free.

Healthcare Professional Queries

For medical and supply queries, our medical information department can be contacted for further information at medinfo.australia@sanofi.com or 1800 818 806 

References: 1. Optisulin Product Information December 2019